In the last trading session, 8.42 million shares of the Petros Pharmaceuticals Inc (NASDAQ:PTPI) were traded, and its beta was 2.03. Most recently the company’s share price was $0.10, and it changed around $0.0 or 2.04% from the last close, which brings the market valuation of the company to $2.52M. PTPI currently trades at a discount to its 52-week high of $1.75, offering almost -1650.0% off that amount. The share price’s 52-week low was $0.09, which indicates that the current value has risen by an impressive 10.0% since then.

Petros Pharmaceuticals Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended PTPI as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Petros Pharmaceuticals Inc is expected to report earnings per share of 0 for the current quarter.

Petros Pharmaceuticals Inc (NASDAQ:PTPI) trade information

Instantly PTPI has showed a green trend with a performance of 2.04% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.1370 on recent trading dayincreased the stock’s daily price by 27.01%. The company’s shares are currently down -74.66% year-to-date, but still down -15.06% over the last five days. On the other hand, Petros Pharmaceuticals Inc (NASDAQ:PTPI) is -64.98% down in the 30-day period.

PTPI Dividends

Petros Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in April.

Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 35.02 shares worth $3495.0, making up 0.31% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 31.81 shares worth around $3174.0, which represents about 0.28% of the total shares outstanding.